heatmaps Search Results


90
GraphPad Software Inc heatmaps
Heatmaps, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heatmaps/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
heatmaps - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Qlucore Inc heat map and pca analysis
Heat Map And Pca Analysis, supplied by Qlucore Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heat map and pca analysis/product/Qlucore Inc
Average 90 stars, based on 1 article reviews
heat map and pca analysis - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
RStudio heatmap package
Heatmap Package, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heatmap package/product/RStudio
Average 90 stars, based on 1 article reviews
heatmap package - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Broad Institute Inc heatmap visualization
Heatmap Visualization, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heatmap visualization/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
heatmap visualization - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Broad Institute Inc heatmaps for individual genes of interest
Heatmaps For Individual Genes Of Interest, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heatmaps for individual genes of interest/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
heatmaps for individual genes of interest - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Lunit Inc activation heatmaps lunit insight mmg
Activation Heatmaps Lunit Insight Mmg, supplied by Lunit Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/activation heatmaps lunit insight mmg/product/Lunit Inc
Average 90 stars, based on 1 article reviews
activation heatmaps lunit insight mmg - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Verlag GmbH heat-maps
Heat Maps, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heat-maps/product/Verlag GmbH
Average 90 stars, based on 1 article reviews
heat-maps - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
RStudio heat maps
Heat Maps, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heat maps/product/RStudio
Average 90 stars, based on 1 article reviews
heat maps - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Broad Institute Inc online morpheus heatmap software
a ELISA titration curves against the SARS-CoV-2 receptor-binding domain (RBD) for IgM, IgG, and IgA in COVID-19 respiratory and paired plasma samples and non-COVID-19 respiratory samples as negative controls. Dotted lines within each graph indicates the cut-off used to determine end-point titres. b End-point titres of SARS-CoV-2 RBD antibodies between top left panel: respiratory samples of COVID-19 and non-COVID-19 patients, top right panel: respiratory and paired plasma samples of COVID-19 patients, and bottom panel: endotracheal tube aspirate (ETA), sputum, or bronchoalveolar lavage (BAL) and paired plasma samples of COVID-19 patients. Top left panel: Bars indicate median with interquartile range. Dotted line indicates the detection level. n ETA = 15, n Sputum = 20, n BAL = 6, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Top right panel: Dotted lines connect the most closely matched plasma and respiratory samples from each patient. Bottom panel: Bars indicate the median. Statistical significance was determined with a two-sided Mann-Whitney test. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. c <t>Heatmap</t> of percentage (%) inhibition tested by surrogate virus neutralization test (sVNT), anti-RBD ELISA titres and days post disease onset. d Correlation between anti-RBD antibody titres and (%) sVNT inhibition. Correlation was determined with a two-tailed Spearman’s correlation. e Number of samples and patients with seroconverted anti-RBD IgM, IgG, IgA and positive % sVNT inhibition. Red curved lines surrounding the donut graphs indicate the samples/patients with seroconverted IgM and IgG. Earliest samples were used for each patient when determining seroconversion which was defined as average titre + 2×SD of non-COVID-19 respiratory samples. Positive % sVNT inhibition was defined as % sVNT inhibition ≥ 20%. f Correlation of anti-RBD ELISA titres and % sVNT inhibition between respiratory samples (ETA, sputum, and BAL) and paired plasma samples collected at the closest timepoint for each patient. Correlation was determined with a two-tailed Spearman’s correlation. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. Source data are provided as a Source Data file.
Online Morpheus Heatmap Software, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/online morpheus heatmap software/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
online morpheus heatmap software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc heat-map
a ELISA titration curves against the SARS-CoV-2 receptor-binding domain (RBD) for IgM, IgG, and IgA in COVID-19 respiratory and paired plasma samples and non-COVID-19 respiratory samples as negative controls. Dotted lines within each graph indicates the cut-off used to determine end-point titres. b End-point titres of SARS-CoV-2 RBD antibodies between top left panel: respiratory samples of COVID-19 and non-COVID-19 patients, top right panel: respiratory and paired plasma samples of COVID-19 patients, and bottom panel: endotracheal tube aspirate (ETA), sputum, or bronchoalveolar lavage (BAL) and paired plasma samples of COVID-19 patients. Top left panel: Bars indicate median with interquartile range. Dotted line indicates the detection level. n ETA = 15, n Sputum = 20, n BAL = 6, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Top right panel: Dotted lines connect the most closely matched plasma and respiratory samples from each patient. Bottom panel: Bars indicate the median. Statistical significance was determined with a two-sided Mann-Whitney test. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. c <t>Heatmap</t> of percentage (%) inhibition tested by surrogate virus neutralization test (sVNT), anti-RBD ELISA titres and days post disease onset. d Correlation between anti-RBD antibody titres and (%) sVNT inhibition. Correlation was determined with a two-tailed Spearman’s correlation. e Number of samples and patients with seroconverted anti-RBD IgM, IgG, IgA and positive % sVNT inhibition. Red curved lines surrounding the donut graphs indicate the samples/patients with seroconverted IgM and IgG. Earliest samples were used for each patient when determining seroconversion which was defined as average titre + 2×SD of non-COVID-19 respiratory samples. Positive % sVNT inhibition was defined as % sVNT inhibition ≥ 20%. f Correlation of anti-RBD ELISA titres and % sVNT inhibition between respiratory samples (ETA, sputum, and BAL) and paired plasma samples collected at the closest timepoint for each patient. Correlation was determined with a two-tailed Spearman’s correlation. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. Source data are provided as a Source Data file.
Heat Map, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heat-map/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
heat-map - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Illumina Inc copy-number heatmaps
a ELISA titration curves against the SARS-CoV-2 receptor-binding domain (RBD) for IgM, IgG, and IgA in COVID-19 respiratory and paired plasma samples and non-COVID-19 respiratory samples as negative controls. Dotted lines within each graph indicates the cut-off used to determine end-point titres. b End-point titres of SARS-CoV-2 RBD antibodies between top left panel: respiratory samples of COVID-19 and non-COVID-19 patients, top right panel: respiratory and paired plasma samples of COVID-19 patients, and bottom panel: endotracheal tube aspirate (ETA), sputum, or bronchoalveolar lavage (BAL) and paired plasma samples of COVID-19 patients. Top left panel: Bars indicate median with interquartile range. Dotted line indicates the detection level. n ETA = 15, n Sputum = 20, n BAL = 6, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Top right panel: Dotted lines connect the most closely matched plasma and respiratory samples from each patient. Bottom panel: Bars indicate the median. Statistical significance was determined with a two-sided Mann-Whitney test. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. c <t>Heatmap</t> of percentage (%) inhibition tested by surrogate virus neutralization test (sVNT), anti-RBD ELISA titres and days post disease onset. d Correlation between anti-RBD antibody titres and (%) sVNT inhibition. Correlation was determined with a two-tailed Spearman’s correlation. e Number of samples and patients with seroconverted anti-RBD IgM, IgG, IgA and positive % sVNT inhibition. Red curved lines surrounding the donut graphs indicate the samples/patients with seroconverted IgM and IgG. Earliest samples were used for each patient when determining seroconversion which was defined as average titre + 2×SD of non-COVID-19 respiratory samples. Positive % sVNT inhibition was defined as % sVNT inhibition ≥ 20%. f Correlation of anti-RBD ELISA titres and % sVNT inhibition between respiratory samples (ETA, sputum, and BAL) and paired plasma samples collected at the closest timepoint for each patient. Correlation was determined with a two-tailed Spearman’s correlation. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. Source data are provided as a Source Data file.
Copy Number Heatmaps, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/copy-number heatmaps/product/Illumina Inc
Average 90 stars, based on 1 article reviews
copy-number heatmaps - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Partek heat maps
a ELISA titration curves against the SARS-CoV-2 receptor-binding domain (RBD) for IgM, IgG, and IgA in COVID-19 respiratory and paired plasma samples and non-COVID-19 respiratory samples as negative controls. Dotted lines within each graph indicates the cut-off used to determine end-point titres. b End-point titres of SARS-CoV-2 RBD antibodies between top left panel: respiratory samples of COVID-19 and non-COVID-19 patients, top right panel: respiratory and paired plasma samples of COVID-19 patients, and bottom panel: endotracheal tube aspirate (ETA), sputum, or bronchoalveolar lavage (BAL) and paired plasma samples of COVID-19 patients. Top left panel: Bars indicate median with interquartile range. Dotted line indicates the detection level. n ETA = 15, n Sputum = 20, n BAL = 6, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Top right panel: Dotted lines connect the most closely matched plasma and respiratory samples from each patient. Bottom panel: Bars indicate the median. Statistical significance was determined with a two-sided Mann-Whitney test. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. c <t>Heatmap</t> of percentage (%) inhibition tested by surrogate virus neutralization test (sVNT), anti-RBD ELISA titres and days post disease onset. d Correlation between anti-RBD antibody titres and (%) sVNT inhibition. Correlation was determined with a two-tailed Spearman’s correlation. e Number of samples and patients with seroconverted anti-RBD IgM, IgG, IgA and positive % sVNT inhibition. Red curved lines surrounding the donut graphs indicate the samples/patients with seroconverted IgM and IgG. Earliest samples were used for each patient when determining seroconversion which was defined as average titre + 2×SD of non-COVID-19 respiratory samples. Positive % sVNT inhibition was defined as % sVNT inhibition ≥ 20%. f Correlation of anti-RBD ELISA titres and % sVNT inhibition between respiratory samples (ETA, sputum, and BAL) and paired plasma samples collected at the closest timepoint for each patient. Correlation was determined with a two-tailed Spearman’s correlation. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. Source data are provided as a Source Data file.
Heat Maps, supplied by Partek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heat maps/product/Partek
Average 90 stars, based on 1 article reviews
heat maps - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


a ELISA titration curves against the SARS-CoV-2 receptor-binding domain (RBD) for IgM, IgG, and IgA in COVID-19 respiratory and paired plasma samples and non-COVID-19 respiratory samples as negative controls. Dotted lines within each graph indicates the cut-off used to determine end-point titres. b End-point titres of SARS-CoV-2 RBD antibodies between top left panel: respiratory samples of COVID-19 and non-COVID-19 patients, top right panel: respiratory and paired plasma samples of COVID-19 patients, and bottom panel: endotracheal tube aspirate (ETA), sputum, or bronchoalveolar lavage (BAL) and paired plasma samples of COVID-19 patients. Top left panel: Bars indicate median with interquartile range. Dotted line indicates the detection level. n ETA = 15, n Sputum = 20, n BAL = 6, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Top right panel: Dotted lines connect the most closely matched plasma and respiratory samples from each patient. Bottom panel: Bars indicate the median. Statistical significance was determined with a two-sided Mann-Whitney test. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. c Heatmap of percentage (%) inhibition tested by surrogate virus neutralization test (sVNT), anti-RBD ELISA titres and days post disease onset. d Correlation between anti-RBD antibody titres and (%) sVNT inhibition. Correlation was determined with a two-tailed Spearman’s correlation. e Number of samples and patients with seroconverted anti-RBD IgM, IgG, IgA and positive % sVNT inhibition. Red curved lines surrounding the donut graphs indicate the samples/patients with seroconverted IgM and IgG. Earliest samples were used for each patient when determining seroconversion which was defined as average titre + 2×SD of non-COVID-19 respiratory samples. Positive % sVNT inhibition was defined as % sVNT inhibition ≥ 20%. f Correlation of anti-RBD ELISA titres and % sVNT inhibition between respiratory samples (ETA, sputum, and BAL) and paired plasma samples collected at the closest timepoint for each patient. Correlation was determined with a two-tailed Spearman’s correlation. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity

doi: 10.1038/s41467-022-30088-y

Figure Lengend Snippet: a ELISA titration curves against the SARS-CoV-2 receptor-binding domain (RBD) for IgM, IgG, and IgA in COVID-19 respiratory and paired plasma samples and non-COVID-19 respiratory samples as negative controls. Dotted lines within each graph indicates the cut-off used to determine end-point titres. b End-point titres of SARS-CoV-2 RBD antibodies between top left panel: respiratory samples of COVID-19 and non-COVID-19 patients, top right panel: respiratory and paired plasma samples of COVID-19 patients, and bottom panel: endotracheal tube aspirate (ETA), sputum, or bronchoalveolar lavage (BAL) and paired plasma samples of COVID-19 patients. Top left panel: Bars indicate median with interquartile range. Dotted line indicates the detection level. n ETA = 15, n Sputum = 20, n BAL = 6, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Top right panel: Dotted lines connect the most closely matched plasma and respiratory samples from each patient. Bottom panel: Bars indicate the median. Statistical significance was determined with a two-sided Mann-Whitney test. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. c Heatmap of percentage (%) inhibition tested by surrogate virus neutralization test (sVNT), anti-RBD ELISA titres and days post disease onset. d Correlation between anti-RBD antibody titres and (%) sVNT inhibition. Correlation was determined with a two-tailed Spearman’s correlation. e Number of samples and patients with seroconverted anti-RBD IgM, IgG, IgA and positive % sVNT inhibition. Red curved lines surrounding the donut graphs indicate the samples/patients with seroconverted IgM and IgG. Earliest samples were used for each patient when determining seroconversion which was defined as average titre + 2×SD of non-COVID-19 respiratory samples. Positive % sVNT inhibition was defined as % sVNT inhibition ≥ 20%. f Correlation of anti-RBD ELISA titres and % sVNT inhibition between respiratory samples (ETA, sputum, and BAL) and paired plasma samples collected at the closest timepoint for each patient. Correlation was determined with a two-tailed Spearman’s correlation. n ETA = 15, n ETA matched plasma = 14, n Sputum = 20, n Sputum matched plasma = 19, n BAL = 6, n BAL matched plasma = 3. Source data are provided as a Source Data file.

Article Snippet: Correlations were assessed using two-tailed Spearman’s correlation coefficient ( r s ) and visualized in R v3.6.2 as heatmaps using the corrplot package or using the online Morpheus heatmap software ( https://software.broadinstitute.org/morpheus ; the Broad Institute, MA, USA) and p-values of correlations were corrected for multiple comparisons by FDR in R v3.6.2.

Techniques: Enzyme-linked Immunosorbent Assay, Titration, Binding Assay, Clinical Proteomics, MANN-WHITNEY, Inhibition, Virus, Neutralization, Two Tailed Test